Biosynthetic proline/alanine random coil polypeptides and their uses

Patent metadata

Field	Value
Publication number	US-10844094-B2
Application number	US-201816107590-A
Country	US
Kind code	B2
Filing date	Aug 21, 2018
Priority date	May 21, 2010
Publication date	Nov 24, 2020
Grant date	Nov 24, 2020

Abstract

The present invention relates to a biosynthetic random coil polypeptide or a biosynthetic random coil polypeptide segment or biosynthetic conjugate, in which the biosynthetic random coil polypeptide, the biosynthetic random coil polypeptide segment, or the biosynthetic conjugate comprises an amino acid sequence consisting solely of proline and alanine amino acid residues, wherein the amino acid sequence consists of at least about 50 proline (Pro) and alanine (Ala) amino acid residues. The at least about 50 proline (Pro) and alanine (Ala) amino acid residues may be (a) fconstituent(s) of a heterologous polypeptide or an heterologous polypeptide construct. Also uses and methods of use of these biosynthetic random coil polypeptides or polypeptide segments or conjugates are described.

First claim

The invention claimed is:

1. A nucleic acid molecule encoding a random coil polypeptide consisting of proline and alanine amino acid residues, wherein the random coil consists of at least 150 proline (Pro) and alanine (Ala) amino acid residues; wherein the random coil polypeptide can be incorporated into a drug conjugate comprising the random coil polypeptide conjugated to a drug selected from the group consisting of (a) a biologically active protein or a polypeptide with biological activity and (b) a small molecule drug.

2. A vector comprising the nucleic acid molecule of claim 1 .

3. A host cell comprising the nucleic acid molecule of claim 1 .

4. The host cell according to claim 3 , wherein said host cell is a eukaryotic host cell.

5. The host cell according to claim 4 , wherein said eukaryotic host cell is a fungal or animal cell.

6. The nucleic acid molecule of claim 1 , wherein said random coil polypeptide consists of 150 to 3000 amino acid residues.

7. The nucleic acid molecule of claim 1 , wherein said proline residues constitute more than 10% and less than 75% of the amino acid sequence.

8. The nucleic acid molecule of claim 1 , wherein no more than 6 consecutive amino acid residues are identical.

9. The nucleic acid molecule of claim 1 , wherein said random coil polypeptide comprises an amino acid sequence selected from the group consisting of

(SEQ ID NO: 1)

AAPAAPAPAAPAAPAPAAPA;

(SEQ ID NO: 2)

AAPAAAPAPAAPAAPAPAAP;

(SEQ ID NO: 3)

AAAPAAAPAAAPAAAPAAAP;

(SEQ ID NO: 4)

AAPAAPAAPAAPAAPAAPAAPAAP;

(SEQ ID NO: 5)

APAAAPAPAAAPAPAAAPAPAAAP;

(SEQ ID NO: 6)

AAAPAAPAAPPAAAAPAAPAAPPA;

and

(SEQ ID NO: 51)

APAPAPAPAPAPAPAPAPAP

and
circular permuted versions or (a) multimers(s) of these sequences.

10. The nucleic acid molecule of claim 1 , wherein said polypeptide with biological activity is selected from the group consisting of binding proteins, antibody fragments, cytokines, growth factors, hormones, and enzymes.

11. The nucleic acid molecule of claim 1 , wherein said polypeptide with biological activity is selected from the group consisting of antibodies, Fab fragments, F(ab′) 2 fragments, CDR-derived peptidomimetics, single chain variable fragments (scFv), domain antibodies, lectins, immunoglobulin domains, fibronectin domains, protein A domains, SH3 domains, ankyrin repeat domains, and lipocalins.

12. The nucleic acid molecule of claim 1 , wherein said biologically active protein is selected from the group consisting of granulocyte colony stimulating factor, human growth hormone, alpha-interferon, beta-interferon, gamma-interferon, tumor necrosis factor, erythropoietin, coagulation factor VIII, gp120/gp160, soluble tumor necrosis factor I and II receptor, reteplase, exendin-4, anakinra, interleukin-2, neutrophil gelatinase-associated lipocalin, follicle-stimulating hormone, glucocerebrosidase, thymosin alpha 1, glucagon, somatostatin, adenosine deaminase, interleukine 11, coagulation factor Vila, coagulation factor IX, hematide, lambda-interferon, leptin, interleukin-22 receptor subunit alpha (IL-22ra), interleukin-22, hyaluronidase, fibroblast growth factor 18, fibroblast growth factor 21, glucagon-like peptide 1, osteoprotegerin, IL-18 binding protein, growth hormone releasing factor, soluble TACI receptor, thrombospondin-1, soluble VEGF receptor Flt-1, and IL-4 mutein.

13. The nucleic acid molecule of claim 1 , whereby said random coil polypeptide mediates an increased in vivo and/or in vitro stability of said drug conjugate.

14. The nucleic acid molecule of claim 13 , wherein said increased in vivo stability is a prolonged plasma half-life of said drug conjugate when compared to the stability of a control polypeptide or a control conjugate lacking said random coil polypeptide.

15. The nucleic acid molecule according to claim 1 , wherein said small molecule drug is selected from the group consisting of digoxigenin, fluorescein, doxorubicin, calicheamicin, camptothecin, fumagillin, dexamethasone, geldanamycin, paclitaxel, docetaxel, irinotecan, cyclosporine, buprenorphine, naltrexone, naloxone, vindesine, vancomycin, risperidone, aripiprazole, palonosetron, granisetron, cytarabine NX1838, leuprolide, goserelin, buserelin, octreotide, teduglutide, cilengitide, abarelix, enfuvirtide, ghrelin, alpha 4 integrin inhibitors, antisense nucleic acids, small interference RNAs, micro RNAs, steroids, DNA or RNA aptamers, peptides, and peptidomimetics.

16. The nucleic acid molecule according to claim 1 , wherein the biologically active protein is selected from the group consisting of binding proteins, antibody fragments, cytokines, growth factors, hormones, and enzymes.

17. A nucleic acid molecule encoding a drug conjugate, the drug conjugate comprising
(i) a random coil polypeptide consisting of proline and alanine amino acid residues, wherein the random coil consists of at least 150 proline (Pro) and alanine (Ala) amino acid residues; and
(ii) a biologically active protein or a polypeptide with biological activity.

18. The nucleic acid molecule of claim 17 , wherein the random coil polypeptide is encoded before or behind the biologically active protein or polypeptide with biological activity in a 5′ to 3′ orientation within the nucleic acid molecule.

19. The nucleic acid molecule of claim 17 further comprising a protease and/or a chemical cleavage site and/or a recognition site between the random coil polypeptide and the biologically active protein or polypeptide with biological activity.

20. The nucleic acid molecule according to claim 17 wherein the biologically active protein is selected from the group consisting of binding proteins, antibody fragments, cytokines, growth factors, hormones, and enzymes.

21. The nucleic acid molecule according to claim 17 further

Assignees

• Univ Muenchen Tech
• Xl Protein Gmbh

Inventors

• Skerra Arne
• Binder Uli
• Schlapschy Martin

Classifications

• A61P1/16 Primary

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title